A termk nem ajnlott gyermekek, terhes s szoptat nk szmra
Tirzepatides unique dual agonism provides synergistic effects that often surpass single-receptor incretin therapies, making it a powerful tool for investigating appetite regulation, glucose homeostasis, energy balance, lipid metabolism, and body composition in obesity, type 2 diabetes, and cardiometabolic models
The Lancet, 407(10531), 892908
Spontaneous reports through systems like the MHRA Yellow Card scheme cannot establish frequency or definitively confirm causality
Incretins are a group of gastrointestinal hormones that cause an increase in the amount of insulin released from the beta cells of the islets of Langerhans after eating
Phase 2 trials show an average weight loss of 24% after 48 weeks on the highest dose of 12mg